Back to Search
Start Over
Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
- Source :
-
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry [J Clin Densitom] 2021 Oct-Dec; Vol. 24 (4), pp. 591-596. Date of Electronic Publication: 2021 Jan 22. - Publication Year :
- 2021
-
Abstract
- Denosumab discontinuation results in rapid bone loss and increased risk of multiple rebound-associated vertebral fractures (RAVFs). The optimal treatment for patients who have sustained such fractures is currently unknown. We aimed to investigate the bone mineral density (BMD) changes achieved with various regimens in postmenopausal women who had sustained RAVFs after denosumab discontinuation in everyday clinical practice. In this multicenter, retrospective observational study, 39 Greek postmenopausal women from six regional bone centers throughout Greece with RAVFs after denosumab discontinuation were included. We collected BMD and fracture data before and 1 year after treatment with denosumab (n = 20), teriparatide (n = 8), zoledronate (n = 8) or teriparatide/denosumab combination (n = 3). Both lumbar spine (LS)-- and femoral neck (FN)-BMD were preserved with all regimens used. With the exception of zoledronate, a trend towards increase was observed with all regimens in LS-BMD. Three patients sustained additional fractures despite treatment reinstitution (2 with zoledronate and 1 with teriparatide). Among patients with RAVFs following denosumab discontinuation both antiresorptive (zoledronate and denosumab) and anabolic (teriparatide) treatment as well as the combination of denosumab with teriparatide seem to be effective in terms of BMD response.<br /> (Copyright © 2021 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Bone Density
Denosumab therapeutic use
Female
Greece
Humans
Postmenopause
Retrospective Studies
Teriparatide therapeutic use
Zoledronic Acid therapeutic use
Bone Density Conservation Agents therapeutic use
Osteoporosis, Postmenopausal diagnostic imaging
Osteoporosis, Postmenopausal drug therapy
Osteoporotic Fractures epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1094-6950
- Volume :
- 24
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
- Publication Type :
- Academic Journal
- Accession number :
- 33541775
- Full Text :
- https://doi.org/10.1016/j.jocd.2021.01.006